Non Small Cell Lung Cancer Clinical Trials in The Bronx, New York

11 studies are recruiting for non small cell lung cancer in The Bronx, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Site, The Bronx, New York

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult par…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Montefiore Medical Center - Einstein Campus /ID# 277169, The Bronx, New York

   Locations

   81 in total

   Run by

   AbbVie

   See if you can join NCT06568939 on ClinicalTrials.gov

3. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

   The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Local Institution - 0357, The Bronx, New York

   Locations

   326 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06561386 on ClinicalTrials.gov

4. Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

   This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery o…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Montefiore Medical Center- Montefiore Medical Park, The Bronx, New York

   Locations

   87 in total

   Run by

   Pfizer

   See if you can join NCT07227298 on ClinicalTrials.gov

5. A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

   The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Montefiore Medical Center - Montefiore Medical Park, The Bronx, New York

   Locations

   71 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05789082 on ClinicalTrials.gov

6. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

   The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Montefiore Einstein Cancer Center, The Bronx, New York

   Locations

   280 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06793215 on ClinicalTrials.gov

7. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Montefiore Medical Center, The Bronx, New York

   Locations

   153 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

8. Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

   This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Montefiore Medical Cancer Center, The Bronx, New York

   Locations

   8 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06745882 on ClinicalTrials.gov

9. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

   The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Montefiore Medical Center- Montefiore Medical Park-Oncology ( Site 0080), The Bronx, New York

   Locations

   229 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06077760 on ClinicalTrials.gov

10. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Montefiore Medical Center, The Bronx, New York

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

11. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Montefiore Medical Center-Einstein Campus, The Bronx, New York

    Locations

    75 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT06686771 on ClinicalTrials.gov